Medical disclaimer · reviewed August 2026

This is price information, not medical advice

Nothing on this site is medical advice, and no listing is a recommendation to start, stop, or change any medication.

Not a substitute for professional care

Tirzepatide is a prescription medicine. Whether it is appropriate for you, at what dose, and alongside whatever else you take, is a decision for a licensed prescriber who knows your history. Reading a price here tells you what something costs. It tells you nothing about whether you should take it.

Do not delay seeking care, and do not disregard advice you have already been given, because of something you read on this site. If what you find here disagrees with what your prescriber or your pharmacist told you, theirs is the account with your chart behind it.

No clinician–patient relationship

Using this site does not create a clinician–patient relationship with anyone, and writing to us does not either. We are not a pharmacy, not a compounder, not a telehealth provider, not a prescriber, and not anyone’s clinician. We do not review anyone’s medical information, there is none of it here, and we cannot answer a question about your own treatment — not because of a policy, but because we have no basis on which to answer it.

Nobody here should be described as having assessed a seller’s clinical quality. What is published about a seller is what it charges, on what cycle, on a stated date, and what its own pages say about itself.

What “compounded” means here

Compounded tirzepatide is not an FDA-approved product. The approved products containing tirzepatide are Mounjaro and Zepbound, both from Eli Lilly. A compounded preparation is made by a pharmacy for an individual patient and has not been through FDA review for safety, effectiveness, or manufacturing quality; its concentration, its excipients and its beyond-use date are set by the compounding pharmacy rather than by an approved label.

That distinction runs through this whole site, including the drug-facts pages: the clinical evidence for tirzepatide was generated on the approved product, and a compounded vial does not automatically inherit it. Two vials from two compounders are not necessarily the same strength per milliliter, and a dose written in units on one syringe is not the same dose on another. What is actually different →

The boxed warning

Tirzepatide’s approved labeling carries a boxed warning about the risk of thyroid C-cell tumors. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma, in Multiple Endocrine Neoplasia syndrome type 2, and in known serious hypersensitivity to tirzepatide or its excipients. A compounding pharmacy not printing that warning does not remove it — it attaches to the molecule. The warning in full →

The risks are real, and this site is not where you assess them

The approved labeling documents pancreatitis, gallbladder disease, acute kidney injury from volume depletion, hypoglycemia when combined with insulin or an insulin secretagogue, and gastrointestinal reactions common enough to affect a meaningful share of people who take it. Those are properties of the drug, not of any particular seller, and a cheap vial carries every one of them. What the trials reported →

The drug-facts pages here report what the label and the published trials say. They are not a risk assessment for you, they do not know what else you take, and they cannot weigh any of it against your own history.

Before you start, stop, or change a dose

Talk to your prescriber. That includes switching sellers, which sounds like a purchasing decision and is not entirely one: a different preparation can be a different concentration, and a price that looks like a saving can be a dose change nobody intended. It also includes stopping, restarting after a gap, and anything you read here about titration.

Nothing on this site is a dosing instruction. Where a dose appears, it is quoted from the approved label to explain what a seller is charging for.

Sellers’ own claims are theirs, not ours

We link to sellers we do not control. What they say about outcomes, about their pharmacies, about eligibility, or about what is permitted where you live is their statement and not ours, and a listing here is not an endorsement of it. Where we quote a seller we mark it as a quotation and date it.

A seller holding an FDA warning letter is still listed here, at its real price, with the letter shown on its page — the letter is a fact you should have before you decide, not a reason to keep a seller off a price index. Which sellers hold one →

Where the drug facts come from

Every clinical statement on this site is drawn from the FDA prescribing information for the approved product, cited to its section and its revision date, or from a paper identified by its PubMed ID and checked against the record rather than written from memory. Each page names its sources at the foot and states the month it was reviewed.

Even so, labels are revised and evidence moves. A page here is a description of a document on a stated date, and the current label is always the authority. The drug-facts corpus →

Reporting a side effect

Tell your prescriber and the pharmacy that supplied the medication first. Serious side effects and quality problems — including a vial that looks wrong, arrives warm, or is not labeled as expected — can also be reported to the FDA through MedWatch, at fda.gov/medwatch or by telephone on 1-800-FDA-1088. This site cannot take a report, forward one, or act on one.

In an emergency

Telling us about an error

If something here is factually wrong, we want to fix the record rather than argue about the page. Write to corrections@compoundedtirzepatide.org with the source that shows it. How corrections work →

To the fullest extent permitted by law, this site is provided as it is and we accept no liability for decisions made on the basis of information published here. See the terms.